Home
Live Updates
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting : comparemela.com
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024 KT-253 Phase 1 study ongoing with...
Related Keywords
Illinois ,
United States ,
Watertown ,
Boston ,
Massachusetts ,
Chicago ,
American ,
Justine Koenigsberg ,
Muhammadr Khawaja ,
Jared Gollob ,
Resource Library ,
Exchange Commission ,
Nasdaq ,
Kymera Therapeutics Inc ,
American Society Of Clinical Oncology ,
Honorhealth Research Institute ,
American Society ,
Clinical Oncology ,
Annual Meeting ,
Chief Medical Officer ,
Response Assessments ,
Targeted Protein Degrader ,
Solid Tumors ,
High Grade Myeloid Malignancies ,
Acute Lymphoblastic Leukemia ,
Private Securities Litigation Reform Act ,
Kymera Therapeutics ,
Kymera Therapeutic ,
Annual Report ,
Media Contact ,
comparemela.com © 2020. All Rights Reserved.